THE EUROPE CELL AND GENE THERAPY MARKET IS EXPECTED TO REACH USD 15.15 BILLION BY 2028 FROM USD 2.17 BILLION IN 2022, GROWING AT A CAGR OF 38.20% DURING THE FORECAST PERIOD.

The Europe Cell and Gene Therapy Market Size, Share, & Trends Analysis Report By

  • Product: Cell Therapy and Gene Therapy
  • Application: Oncology, Genetic Disorders, Dermatology, Musculoskeletal, and Others
  • End-user: Hospitals, Cancer Care Centers, and Others
  • Geography: Europe (Germany, France, UK, Italy, Spain, and Rest of Europe)

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2023–2028.

Licence Types What are these?
GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

83 Pages

icon-table

06 Tables

icon-chart

24 Charts

icon-region

1 Regions

icon-country

6 Countries

icon-company

32 Companies

icon-market

4 Market Segment

EUROPE CELL AND GENE THERAPY MARKET REPORT SCOPE

Report Attribute Details
Market Size (2028) USD 15.15 BILLION
Market Size (2022) USD 2.17 BILLION
CAGR (2022-2028) 38.20%
Base Year 2022
Historic Year 2021
Forecast Year 2023-2028
Market Segments Product, Application, End-user, and Geography
Geographic Analysis North America, Europe, APAC, Latin America, and Middle East & Africa

The Europe cell and gene therapy market was valued at USD 2.17 billion in 2022, is projected to cross USD 15.15 billion by 2028, and is growing at a CAGR of 38.20%. Investing in R&D activities to develop novel therapies is key for the long-term sustainability of companies operating in the Europe cell and gene therapy market. Therefore, many players, including key and emerging companies and smaller vendors, are investing in significant R&D activities. Moreover, the major players focus on strategic acquisitions, licensing, and collaboration agreements with emerging players to enter the cell and gene therapy market and gain access to commercially launched products.

In recent years, the Europe cell and gene therapy market has seen both approvals and withdrawals of cell and gene therapies. Most withdrawals seem to be due to a lack of commercial viability for the manufacturers rather than safety concerns. Further, drug developers are prioritizing developing and commercializing CAR-T cell-based gene therapies. Globally, more than 1,000 clinical trials are being conducted on CAR T-cell therapies, of which at least 500 clinical trials are for cancer alone. Kymriah (Novartis), Yescarta (Gilead Sciences), Tecartus (Gilead Sciences), Breyanzi (Bristol Myers Squibb), Abecma (Bristol Myers Squibb), and Carvykti (Janssen Biotech / Legend Biotech) are the commercial CAR-T therapies available in the market.

The European Medicines Agency (EMA) has approved over nineteen cell and gene therapy drugs. Still, the new product pipeline has approximately 193 investigational therapies, with more than half of these in Phase 2 clinical trials. Oncology and rare diseases remain the top areas targeted by gene therapies from preclinical through pre-registration. Also, approximately 1,564 clinical trials are under investigation for various cell and gene therapies in Europe. This increase could be because of increased funding for cell and gene therapy. The industry-sponsored trials continue to dominate with a share of 78.71%. 

MARKET TRENDS & DRIVERS

Robust Cell & Gene Therapy Pipeline
Vendors are conducting clinical trials to gain regulatory approval in countries and regions with huge untapped potential. The Europe cell and gene therapy market vendors are actively conducting clinical studies to gain regulatory approval and extend their presence in these major markets for cell & gene therapy products. European market provides the required facilities for cell & gene therapy product development, so major vendors are entering the European market.

Increase in Strategic Acquisitions
Many vendors are planning to tap the potential of the Europe cell and gene therapy market by developing and commercializing innovative products. This increasing list of potential investigational cell & gene therapy products encourages many companies to make acquisitions an important strategy to penetrate the market further.

Regulatory Support for Cell & Gene Therapies
The European Medicines Agency (EMA) is the centralized regulatory body of the EU. Within the EMA, The Committee for Advanced Therapies (CAT) provides an expert opinion on products and recommends approval or rejection. To protect vendors from competition, they provide orphan designation to the product, as a limited number of patients undergo treatments.

SEGMENTATION INSIGHTS

  • The Europe cell and gene therapy market by product type is classified into cell and gene therapy. In 2022, the gene therapy segment accounted for the most significant. Cell and gene therapy is one of the revolutionary medicines in recent times, providing promising results in various cancer treatments for rare genetic disorders in patients. Furthermore, the number of clinical trials investigating gene therapies is increasing in Europe despite the limited number of products that have successfully reached the industry.
  • The hospital end-user segment accounted for the most prominent share of the Europe cell and gene therapy market in 2022. Hospitals being the first point of care for any disease condition, and cell and gene therapies demanding advanced equipment and skilled professionals available in hospitals prompts most patients to prefer hospitals to other clinics or centers.
  • The European cell and gene therapy industry by application type is classified into oncology, genetic disorders, dermatology, musculoskeletal, and others. In 2022, the oncology segment dominated the segmental share of the European industry.

REGIONAL ANALYSIS

Germany was the first-largest cell and gene therapy market among EU5, followed by France and the UK in 2022. The growth of the Europe cell and gene therapy market can be attributed to the rising target patient population, regulatory body support, and higher access to healthcare due to well-established healthcare infrastructure. Furthermore, Italy and Germany are introducing innovative payment methods for expensive cell & gene therapy products, thus motivating patients to opt for advanced medical products such as cell therapy and gene therapy. In addition to sophisticated healthcare infrastructure, healthcare spending in Europe is high, favoring the industry growth during the forecast period.

VENDOR LANDSCAPE

The competitive market in the Europe cell and gene therapy market is intensifying, with players offering a diverse range of products. A few major players dominate the market in terms of market share. Some companies currently dominating the industry are Novartis, Gilead Sciences, Spark Therapeutics (Roche),  Amgen, and Orchard Therapeutics. The major players focus on strategic acquisitions, licensing, and collaboration agreements with emerging players to enter the cell and gene therapy market and gain access to commercially launched products. For instance, Novartis operates through two business segments: Innovative Medicines, which promotes innovative patent-protected prescription medicines, and Sandoz, under which it produces and markets generic pharmaceuticals and biosimilars. The Innovative Medicines division is further segmented into the oncology and pharmaceutical business units. The major products target therapeutic conditions such as neuroscience, immunology, oncology, ophthalmology, and hematology. Further, some companies currently dominating the cell therapy industry are Organogenesis, Smith + Nephew, Vericel, and others.

Frequently Asked Questions

How big is the Europe cell and gene therapy market?

The Europe cell and gene therapy market size was valued at USD 2.17 billion in 2022 and is expected to reach USD 15.15 billion by 2028.

What is the growth rate of the Europe cell and gene therapy market?

The Europe cell and gene therapy market is expected to grow at a CAGR of 38.20% from 2023 to 2029.

What are the significant trends in the European cell and gene therapy industry?

CMOs offering vector manufacturing services for cell & gene therapy companies, robust cell & gene therapy pipelines, and increased strategic acquisitions are significant trends in the European cell and gene therapy industry.

Download Free Sample

The Europe cell and gene therapy market size is expected to grow at a CAGR of approximately 38.20% from 2022 to 2028.

The following factors are likely to contribute to the growth of the Europe cell and gene therapy market during the forecast period:

  • Regulatory Support for Cell & Gene Therapies
  • Increasing Demand for CAR-T therapies in Europe
  • Product Launches & Approvals

Base Year: 2022

Forecast Year: 2023-2028

The report considers the present scenario of the Europe cell and gene therapy market and its market dynamics for 2023−2028. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.

Competitive Landscape – Gene Therapies

Key Company Profiles

  • Novartis
    • Business Overview
    • Product Offerings
  • Gilead Sciences
  • Amgen
  • Roche

Other Prominent Vendors

  • Orchard Therapeutics
    • Business Overview
    • Product Offerings
  • BioMarin Pharmaceutical (BioMarin)
  • PTC Therapeutics
  • Bristol-Myers Squibb (BMS)
  • Legend Biotech
  • bluebird bio
  • Human Stem Cells Institute PJSC (HSCI)

Competitive Landscape – Cell Therapies

  • Organogenesis
    • Business Overview
    • Product Offerings
  • Smith & Nephew
  • CHIESI Farmaceutici
  • CollPlant
  • DON
  • Takeda Pharmaceutical Company
  • Nipro
  • Vericel
  • NuVasive

Key Emerging Investigational Vendors

  • Adaptimmune Therapeutics
  • AgenTus Therapeutics
  • Autolus Therapeutics
  • Cellectis
  • Celyad
  • CombiGene AB
  • Eukarys
  • FREELINE Therapeutics
  • Innoskel
  • Psioxus Therapeutics
  • Sparing Vision
  • UniQure

Segmentation by Product

  • Cell Therapy
  • Gene Therapy

Segmentation by Application

  • Oncology
  • Genetic Disorders
  • Dermatology
  • Musculoskeletal
  • Others

Segmentation by End-user

  • Hospitals
  • Cancer Care Centers
  • Others

Segmentation by Geography

  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe

CHAPTER – 1: Cell & Gene Therapy Market Overview 

  • Executive Summary 
  • Introduction 
  • Key Findings 
  • Key Developments 

CHAPTER – 2: Cell & Gene Therapy Market Segmentation Data 

  • Europe: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions) 
    • Product Type 
    • Application type 
    • End-user type 
  • EU5: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions) 
    • Product Type 
    • Application type 
    • End-user type 
  • ROEU: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions) 
    • Product Type 
    • Application type 
    • End-user type 
  • Germany: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions) 
    • Product Type 
  • France: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions) 
    • Product Type 
  • UK: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions) 
    • Product Type 
  • Italy: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions) 
    • Product Type 
  • Italy: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions) 
    • Product Type 

CHAPTER – 3: Cell & Gene Therapy Prospects & Opportunities 

  • Cell & Gene Therapy Market Drivers 
  • Cell & Gene Therapy Market Trends 
  • Cell & Gene Therapy Market Constraints 

CHAPTER – 4: Cell & Gene Therapy Industry Overview 

  • Cell & Gene Therapy - Marketed Drugs Overview 
  • Cell & Gene Therapy - Pipeline Drugs Overview 
  • Cell & Gene Therapy - Competitive Landscape 
  • Cell & Gene Therapy - Key Players 
  • Cell & Gene Therapy - Key Company Profiles 
  • Cell & Gene Therapy - Mergers & Acquisitions 
  • Cell & Gene Therapy - Key Strategic Recommendations  

CHAPTER – 5: Pricing and Reimbursement Scenario 

  • Pricing, Reimbursement, and Market Access 
  • Contract Manufacturing Organizations (CMOs) 
  • Regulatory Landscape and Policies 

CHAPTER – 6: Appendix 

  • Research Methodology 
  • Abbreviations 
  • About Arizton 

List of Exhibits 

  • Exhibit 1: Projected Revenue of Cell & Gene Therapy Market in Europe (2022 – 2028) 
  • Exhibit 2: Projected Revenue of Cell & Gene Therapy Market in Europe by Product Type (2022 – 2028) 
  • Exhibit 3: Projected Revenue of Cell & Gene Therapy Market in Europe by Application Type (2022 – 2028) 
  • Exhibit 4: Projected Revenue of Cell & Gene Therapy Market in Europe by End-user Type (2022 – 2028) 
  • Exhibit 5: Projected Revenue of Cell & Gene Therapy Market in EU5 (2022 – 2028) 
  • Exhibit 6: Projected Revenue of Cell & Gene Therapy Market in EU5 by Product Type (2022 – 2028) 
  • Exhibit 7: Projected Revenue of Cell & Gene Therapy Market in EU5 by Application Type (2022 – 2028) 
  • Exhibit 8: Projected Revenue of Cell & Gene Therapy Market in EU5 by End-user Type (2022 – 2028) 
  • Exhibit 9: Projected Revenue of Cell & Gene Therapy Market in ROEU (2022 – 2028) 
  • Exhibit 10: Projected Revenue of Cell & Gene Therapy Market in ROEU by Product Type (2022 – 2028) 
  • Exhibit 11: Projected Revenue of Cell & Gene Therapy Market in ROEU by Application Type (2022 – 2028) 
  • Exhibit 12: Projected Revenue of Cell & Gene Therapy Market in ROEU by End-user Type (2022 –2028) 
  • Exhibit 13: Projected Revenue of Cell & Gene Therapy Market in Germany (2022 – 2028) 
  • Exhibit 14: Projected Revenue of Cell & Gene Therapy Market in Germany by Product Type (2022 – 2028) 
  • Exhibit 15: Projected Revenue of Cell & Gene Therapy Market in France (2022 – 2028) 
  • Exhibit 16: Projected Revenue of Cell & Gene Therapy Market in France by Product Type (2022 – 2028) 
  • Exhibit 17: Projected Revenue of Cell & Gene Therapy Market in UK (2022 – 2028) 
  • Exhibit 18: Projected Revenue of Cell & Gene Therapy Market in UK by Product Type (2022 – 2028) 
  • Exhibit 19: Projected Revenue of Cell & Gene Therapy Market in Italy (2022 – 2028) 
  • Exhibit 20: Projected Revenue of Cell & Gene Therapy Market in Italy by Product Type (2022 – 2028) 
  • Exhibit 21: Projected Revenue of Cell & Gene Therapy Market in Spain (2022 – 2028) 
  • Exhibit 22: Projected Revenue of Cell & Gene Therapy Market in Spain by Product Type (2022 – 2028) 
  • Exhibit 23: Marketed Drugs Overview in Cell & Gene Therapy Market 
  • Exhibit 24: Pipeline Drugs Overview in Cell & Gene Therapy Market 

List of Tables 

  • Table 1: Key Market Trends in Cell & Gene Therapy Market 
  • Table 2: Key Market Enablers in Cell & Gene Therapy Market 
  • Table 3: Key Market Constraints in Cell & Gene Therapy Market 
  • Table 4: Recent Approvals in Cell & Gene Therapy Market 
  • Table 5: Near-term Approvals in Cell & Gene Therapy Market 

Select a license type that suits your business needs

single-user Single User Licence
$2500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$2999.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$3999.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$2000.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Licence Types What are these?

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date